Zobrazeno 1 - 10
of 29
pro vyhledávání: '"V. J. Sinibaldi"'
Autor:
Danai Daliani, William L. Dahut, Glenn J. Bubley, Boris Freidlin, Nancy A. Dawson, Eric J. Small, Robin T. Vollmer, Daniel P. Petrylak, William D. Figg, William Oh, Mario A. Eisenberger, V. J. Sinibaldi, Maha Hussain, Howard I. Scher, Charles E. Myers, Matthew R. Smith, Eddie Reed, Gary R. Hudes, Michael A. Carducci, Oliver Sartor, Richard Kaplan, Susan Halabi, Jonathan W. Simons, George Wilding, Donald L. Trump, Bruce J. Roth
Publikováno v:
Journal of Clinical Oncology. 17:3461-3467
PURPOSE: Prostate-specific antigen (PSA) is a glycoprotein that is found almost exclusively in normal and neoplastic prostate cells. For patients with metastatic disease, changes in PSA will often antedate changes in bone scan. Furthermore, many but
Autor:
V. J. Sinibaldi, Maya Gottfried, Hans J. Hammers, V. Neiman, Svetlana Kovel, Daniel Keizman, Avivit Neumann, Mario A. Eisenberger, Michael A. Carducci, Eliahu Gez, Raanan Berger, Avivit Peer, Wilmosh Mermershtain, Ariel Hammerman, Nimrod Maimon, Eli Rosenbaum, Avishay Sella, Keren Rouvinov, David Sarid, Ilan Feldhamer
Publikováno v:
European Urology Supplements. 15:e1740
Autor:
Eli Rosenbaum, Igal Kushnir, Eliahu Gez, Mario A. Eisenberger, Raanan Berger, Avivit Neumann, Wilmosh Mermershtain, Keren Rouvinov, V. J. Sinibaldi, Svetlana Kovel, Nimrod Maimon, Maya Gottfried, David Sarid, Michael A. Carducci, Avivit Peer, Avishay Sella, V. Neiman, Hans J. Hammers, Daniel Keizman
Publikováno v:
European Urology Supplements. 15:e1741
Autor:
Duncan I. Jodrell, S C Jacobs, Eleanor G. Zuhowski, Katherine Tkaczuk, Ramzi K. Hemady, Mario A. Eisenberger, M H Lowitt, V. J. Sinibaldi, Rajeshwari Sridhara, Leonard M. Reyno
Publikováno v:
Journal of Clinical Oncology. 13:2174-2186
PURPOSE This phase I study was designed with the following objectives: (1) to describe the overall and dose-limiting toxicity (DLT) of suramin administered by intermittent short intravenous infusions until DLT or disease progression; (2) to determine
Autor:
Avishay Sella, Maya Gottfried, Daniel Keizman, Eli Rosenbaum, Eliahu Gez, V. J. Sinibaldi, Hans J. Hammers, Mario A. Eisenberger, Raanan Berger, David Sarid, Avivit Peer, Nimrod Maimon, Keren Rouvinov, Jae-Lyun Lee, Michael A. Carducci, V. Neiman, Wilmosh Mermershtain
Publikováno v:
European Urology Supplements. 13:106
Autor:
Michael A. Carducci, Maya Gottfried, Avivit Neumann, Svetlana Kovel, Eliahu Gez, Avivit Peer, V. J. Sinibaldi, Mario A. Eisenberger, Hans J. Hammers, Eli Rosenbaum, David Sarid, Daniel Keizman, V. Neiman, Avishay Sella, Wilmosh Mermershtain, Raanan Berger, Keren Rouvinov
Publikováno v:
European Urology Supplements. 13:158
Autor:
Daniel Keizman, M. Mishaeli, Avivit Peer, Nimrod Maimon, Avishay Sella, Maya Gottfried, Svetlana Kovel, V. J. Sinibaldi, Avivit Neumann, Mario A. Eisenberger, Michael A. Carducci
Publikováno v:
European Urology Supplements. 13:137
Autor:
Maya Gottfried, Keren Rouvinov, Eliahu Gez, Daniel Keizman, Avishay Sella, Hans J. Hammers, Michael A. Carducci, Avivit Peer, Mario A. Eisenberger, V. Neiman, Wilmosh Mermershtain, Henry Hayat, V. J. Sinibaldi, Raanan Berger, Eli Rosenbaum, David Sarid
Publikováno v:
European Urology Supplements. 13:161
Publikováno v:
The Journal of urology. 164(1)
We summarized and critically assessed all available data from phase III clinical trials on complete androgen blockade versus surgical or medical castration alone.Published results in journals and abstracts of phase III trials, and published meta-anal
Publikováno v:
Cancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 7(7)
Hormone-refractory prostate cancer (HRPC) patients often have nonmeasurable disease. In such patients, predictive biomarkers other than tumor response may be required to compare therapeutic effects. We examined the predictive value for survival of va